$14.99
00.00%
Pre-Market: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Enanta Pharma
ENTANASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Enanta Pharma (NASDAQ:ENTA) Stock, Analyst Ratings, Price Targets, Forecasts
Enanta Pharmaceuticals Inc has a consensus price target of $51.15 based on the ratings of 13 analysts. The high is $116 issued by JMP Securities on November 23, 2021. The low is $11 issued by JP Morgan on February 8, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., JMP Securities, and JP Morgan on May 7, 2024, May 7, 2024, and February 8, 2024, respectively. With an average price target of $20 between HC Wainwright & Co., JMP Securities, and JP Morgan, there's an implied 33.42% upside for Enanta Pharmaceuticals Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JMP Securities
JP Morgan
Oppenheimer
RBC Capital
1calculated from analyst ratings
Analyst Ratings for Enanta Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2024 | Buy Now | 80.12% | HC Wainwright & Co. | Ed Arce | $28 → $27 | Maintains | Buy | Get Alert |
| 05/07/2024 | Buy Now | 46.76% | JMP Securities | Roy Buchanan | $23 → $22 | Maintains | Market Outperform | Get Alert |
| 02/08/2024 | Buy Now | -26.62% | JP Morgan | Eric Joseph | $12 → $11 | Maintains | Underweight | Get Alert |
| 11/22/2023 | Buy Now | 40.09% | Oppenheimer | Jay Olson | $25 → $21 | Maintains | Perform | Get Alert |
| 11/21/2023 | Buy Now | 86.79% | HC Wainwright & Co. | Ed Arce | $30 → $28 | Maintains | Buy | Get Alert |
| 11/21/2023 | Buy Now | 53.44% | JMP Securities | Roy Buchanan | $42 → $23 | Maintains | Outperform | Get Alert |
| 10/23/2023 | Buy Now | 100.13% | HC Wainwright & Co. | Ed Arce | $48 → $30 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | 0.07% | RBC Capital | Brian Abrahams | $25 → $15 | Maintains | Sector Perform | Get Alert |
| 09/19/2023 | Buy Now | 220.21% | HC Wainwright & Co. | Ed Arce | → $48 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | Buy Now | 66.78% | Oppenheimer | Jay Olson | $30 → $25 | Maintains | Perform | Get Alert |
| 08/08/2023 | Buy Now | 220.21% | HC Wainwright & Co. | Ed Arce | → $48 | Reiterates | Buy → Buy | Get Alert |
| 08/08/2023 | Buy Now | 66.78% | RBC Capital | Brian Abrahams | → $25 | Reiterates | Sector Perform → Sector Perform | Get Alert |
| 08/08/2023 | Buy Now | 180.19% | JMP Securities | Roy Buchanan | $65 → $42 | Maintains | Market Outperform | Get Alert |
| 08/08/2023 | Buy Now | 20.08% | Jefferies | Akash Tewari | $49 → $18 | Downgrade | Buy → Hold | Get Alert |
| 05/11/2023 | Buy Now | 100.13% | Oppenheimer | Jay Olson | $50 → $30 | Reiterates | Perform → Perform | Get Alert |
| 05/09/2023 | Buy Now | 120.15% | RBC Capital | Brian Abrahams | $48 → $33 | Maintains | Sector Perform | Get Alert |
| 05/09/2023 | Buy Now | 220.21% | HC Wainwright & Co. | Ed Arce | $68 → $48 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | 333.62% | JMP Securities | Roy Buchanan | $82 → $65 | Maintains | Outperform | Get Alert |
| 03/22/2023 | Buy Now | 260.24% | RBC Capital | Brian Abrahams | → $54 | Reiterates | → Sector Perform | Get Alert |
| 02/09/2023 | Buy Now | 226.88% | SVB Leerink | Roanna Ruiz | → $49 | Reiterates | → Market Perform | Get Alert |
| 02/08/2023 | Buy Now | 480.39% | Piper Sandler | Yasmeen Rahimi | → $87 | Maintains | Overweight | Get Alert |
| 02/08/2023 | Buy Now | 300.27% | JP Morgan | Eric Joseph | $74 → $60 | Maintains | Neutral | Get Alert |
| 01/27/2023 | Buy Now | 226.88% | SVB Leerink | Roanna Ruiz | $50 → $49 | Maintains | Market Perform | Get Alert |
| 12/09/2022 | Buy Now | 273.58% | HC Wainwright & Co. | Ed Arce | → $56 | Initiates | → Buy | Get Alert |
| 11/22/2022 | Buy Now | 260.24% | RBC Capital | Brian Abrahams | $65 → $54 | Maintains | Sector Perform | Get Alert |
| 08/10/2022 | Buy Now | 293.6% | Oppenheimer | Jay Olson | $53 → $59 | Maintains | Perform | Get Alert |
| 08/09/2022 | Buy Now | 813.94% | JMP Securities | Roy Buchanan | $103 → $137 | Maintains | Market Outperform | Get Alert |
| 08/09/2022 | Buy Now | 340.29% | RBC Capital | Brian Abrahams | $67 → $66 | Maintains | Sector Perform | Get Alert |
| 08/01/2022 | Buy Now | 253.57% | Oppenheimer | Jay Olson | $45 → $53 | Maintains | Perform | Get Alert |
| 08/01/2022 | Buy Now | 233.56% | SVB Leerink | Roanna Ruiz | $44 → $50 | Maintains | Market Perform | Get Alert |
| 07/06/2022 | Buy Now | 313.61% | Evercore ISI Group | Liisa Bayko | → $62 | Upgrade | In-Line → Outperform | Get Alert |
| 07/01/2022 | Buy Now | 346.96% | RBC Capital | Brian Abrahams | $64 → $67 | Maintains | Sector Perform | Get Alert |
| 06/01/2022 | Buy Now | 160.17% | Evercore ISI Group | Liisa Bayko | → $39 | Upgrade | Underperform → In-Line | Get Alert |
| 05/20/2022 | Buy Now | 200.2% | Oppenheimer | Jay Olson | $70 → $45 | Maintains | Outperform | Get Alert |
| 05/19/2022 | Buy Now | 500.4% | Baird | Brian Skorney | $130 → $90 | Maintains | Outperform | Get Alert |
| 05/19/2022 | Buy Now | 587.12% | JMP Securities | Roy Buchanan | $114 → $103 | Maintains | Market Outperform | Get Alert |
| 05/19/2022 | Buy Now | 193.53% | SVB Leerink | Roanna Ruiz | $58 → $44 | Maintains | Market Perform | Get Alert |
| 05/12/2022 | Buy Now | 366.98% | Roth Capital | Zegbeh Jallah | $101 → $70 | Maintains | Buy | Get Alert |
| 05/10/2022 | Buy Now | 660.51% | JMP Securities | Roy Buchanan | $116 → $114 | Maintains | Market Outperform | Get Alert |
| 05/10/2022 | Buy Now | 286.92% | SVB Leerink | Roanna Ruiz | $68 → $58 | Maintains | Market Perform | Get Alert |
| 05/10/2022 | Buy Now | 326.95% | RBC Capital | Brian Abrahams | $72 → $64 | Maintains | Sector Perform | Get Alert |
| 02/09/2022 | Buy Now | 353.64% | SVB Leerink | Roanna Ruiz | $80 → $68 | Maintains | Market Perform | Get Alert |
| 01/13/2022 | Buy Now | 433.69% | SVB Leerink | Roanna Ruiz | $85 → $80 | Maintains | Market Perform | Get Alert |
| 11/24/2021 | Buy Now | 386.99% | Oppenheimer | Jay Olson | — | Maintains | Perform | Get Alert |
| 11/23/2021 | Buy Now | 673.85% | JMP Securities | Jason Butler | — | Maintains | Market Outperform | Get Alert |
| 11/23/2021 | Buy Now | 467.04% | SVB Leerink | Roanna Ruiz | — | Maintains | Market Perform | Get Alert |
| 11/19/2021 | Buy Now | 380.32% | RBC Capital | Brian Abrahams | — | Maintains | Sector Perform | Get Alert |
| 11/19/2021 | Buy Now | 640.49% | JMP Securities | Jason Butler | — | Maintains | Market Outperform | Get Alert |
| 11/08/2021 | Buy Now | 707.2% | JMP Securities | Jason Butler | — | Maintains | Market Outperform | Get Alert |
| 11/08/2021 | Buy Now | 513.74% | SVB Leerink | Roanna Ruiz | — | Maintains | Market Perform | Get Alert |
| 10/20/2021 | Buy Now | 393.66% | RBC Capital | Brian Abrahams | — | Maintains | Sector Perform | Get Alert |
| 10/20/2021 | Buy Now | 413.68% | JMP Securities | Jason Butler | — | Maintains | Market Outperform | Get Alert |
| 10/07/2021 | Buy Now | 533.76% | Jefferies | Akash Tewari | — | Initiates | → Buy | Get Alert |
| 09/09/2021 | Buy Now | 266.91% | SVB Leerink | Roanna Ruiz | — | Initiates | → Market Perform | Get Alert |
| 08/09/2021 | Buy Now | 233.56% | RBC Capital | Brian Abrahams | — | Maintains | Sector Perform | Get Alert |
| 08/06/2021 | Buy Now | 233.56% | RBC Capital | Brian Abrahams | — | Maintains | Sector Perform | Get Alert |
| 08/06/2021 | Buy Now | 413.68% | JMP Securities | — | — | Maintains | Market Outperform | Get Alert |
FAQ
What is the target price for Enanta Pharma (ENTA) stock?
The latest price target for Enanta Pharma (NASDAQ:ENTA) was reported by HC Wainwright & Co. on May 7, 2024. The analyst firm set a price target for $27.00 expecting ENTA to rise to within 12 months (a possible 80.12% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Enanta Pharma (ENTA)?
The latest analyst rating for Enanta Pharma (NASDAQ:ENTA) was provided by HC Wainwright & Co., and Enanta Pharma maintained their buy rating.
When was the last upgrade for Enanta Pharma (ENTA)?
The last upgrade for Enanta Pharmaceuticals Inc happened on July 6, 2022 when Evercore ISI Group raised their price target to $62. Evercore ISI Group previously had an in-line for Enanta Pharmaceuticals Inc.
When was the last downgrade for Enanta Pharma (ENTA)?
The last downgrade for Enanta Pharmaceuticals Inc happened on August 8, 2023 when Jefferies changed their price target from $49 to $18 for Enanta Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Enanta Pharma (ENTA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Enanta Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Enanta Pharma was filed on May 7, 2024 so you should expect the next rating to be made available sometime around May 7, 2025.
Is the Analyst Rating Enanta Pharma (ENTA) correct?
While ratings are subjective and will change, the latest Enanta Pharma (ENTA) rating was a maintained with a price target of $28.00 to $27.00. The current price Enanta Pharma (ENTA) is trading at is $14.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.